• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    All News #Library
    Biotech

    Junshi NMPA Accepts Toripalimab SC NDA In 12 Indications

    GLOBENEWSWIRE

    Junshi Accepts NDA For Roconkibart (IL-17A) for Plaque Psoriasis

    GLOBENEWSWIRE

    Junshi Biosciences Meets Primary Endpoints In JS001SC Phase 3

    GLOBENEWSWIRE

    Junshi Gets FDA IND Nod for Ph2/3 NSCLC Study of JS207

    GLOBENEWSWIRE

    Junshi` Phase 3 JS005 Meets Primary Endpoints in Plaque Psoriasis

    GLOBENEWSWIRE

    TREOS, Charité, Junshi Launch Ph2 Trial in MSS Colorectal Cancer

    GLOBENEWSWIRE

    Junshi Biosciences Announces Ongericimab`s sNDA Approval in China

    GLOBENEWSWIRE

    BioDlink Congratulates Junshi Biosciences on JS212 IND Approval

    PR NEWSWIRE

    Junshi Biosciences announces sNDA approval of Toripalimab for 1st

    GLOBENEWSWIRE

    Junshi Gets sNDA Nod For Toripalimab Combo In Liver Cancer

    GLOBENEWSWIRE

    Junshi Partners With LEO Pharma For Toripalimab In Europe

    GLOBENEWSWIRE

    Junshi Biosciences Announces Toripalimab’s Approval in Australia

    GLOBENEWSWIRE

    Junshi Biosciences Gets UK MHRA Approval for Toripalimab

    GLOBENEWSWIRE

    Junshi Biosciences’ Toripalimab Gains Approval In India, Hong Kong

    BIOSPECTRUM

    Junshi Biosciences Toripalimab Approved For Marketing In India

    GLOBENEWSWIRE

    Junshi`s Toripalimab sNDA Accepted For First-Line Melanoma Treatment

    GLOBENEWSWIRE

    Junshi Biosciences Announces Ph3 Study of Toripalimab Combined with Bevacizumab

    GLOBENEWSWIRE

    Junshi Announces JAMA Publication from Phase 3 of Perioperative Toripalimab

    GLOBENEWSWIRE

    Junshi Announces Publication of Results from Phase 3 Trial of Toripalimab

    GLOBENEWSWIRE

    Junshi Announces Approval of Supplemental New Drug Application for Toripalimab

    GLOBENEWSWIRE

    Junshi Announces Chemical Entity Application for Toripalimab Accepted by TGA

    GLOBENEWSWIRE

    Junshi Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023

    GLOBENEWSWIRE

    Junshi Biosciences Announces Collaboration with Dr. Reddy™Toripalimab

    GLOBENEWSWIRE

    Junshi Bios, Rxilient Biotech Partner Develop Toripalimab in Southeast Asia

    CONTRACT PHARMA

    Junshi Bios Announces Establishment of Joint Venture with Rxilient Biotech

    GLOBENEWSWIRE

    Junshi Announces Toripalimab with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in PIII Study

    GLOBENEWSWIRE

    China approves two domestically developed COVID drugs

    REUTERS

    Junshi says toripalimab succeeded in Phase III perioperative NSCLC study

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.